Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Accelerated tenant absorption across the 1.4 million square foot delivery pipeline and closing capital recycling transactions to reduce debt.
Cash rental rate changes on lease renewals dropping below -15.0% or contractual lease downtime extending beyond twenty-four months.
We rate Alexandria Real Estate Equities Hold. At the report-date share price of $41.62, the stock offers modest upside of 3.4% to our Fair value of $43.02. The primary downside risk stems from negative mark-to-market lease renewals and extended vacancy downtime across contractual expirations. Conversely, sustained tenant retention across core mega-campuses and disciplined capital expenditure moderation support operational cash flow stabilization toward Potential value of $49.06.3
Alexandria Real Estate Equities warrants a Hold rating. For an ordinary investor, this indicates that the shares offer fair compensation for holding the asset through contracted dividend distributions, but do not present a compelling valuation discount to warrant new capital deployment.
On the report date, shares traded at $41.62, representing upside of 3.4% to our Fair value midpoint of $43.02 and standing below Potential value of $49.06. Current market valuation closely aligns with fundamental earning power under prevailing market conditions.
The central risk to this thesis is that life science submarket oversupply and slower venture capital funding force negative mark-to-market rental roll-downs on expiring leases. If contractual expirations face prolonged vacancy downtime and larger tenant improvement concessions, property-level net operating income will contract, weakening dividend coverage against $13.17B in total debt.23
The primary path to outperformance relies on tenant switching costs and scarcity value across premier mega-campuses, which generate 95.4% of total revenue. As development capital expenditures taper from peak levels toward normalized maintenance outlays, operational cash flow stabilizes and facilitates debt reduction.36
Specialized wet-lab infrastructure, regulatory zoning entitlements, and cluster agglomeration create significant friction for pharmaceutical tenants to relocate away from Alexandria's mega-campuses.3
Moderating development capital expenditures from peak historical levels toward guided ranges curtails external capital needs and supports balance sheet deleveraging.3
Specialized wet-lab fit-outs, heavy regulatory certifications, and cluster network density create substantial operational friction for pharmaceutical tenants relocating away from mega-campuses, with 68% of 2Q26 leasing generated by existing tenants.3
We rate Alexandria Hold because modest upside of 3.4% to Fair value of $43.02 is balanced by rental rate roll-down headwinds on upcoming lease expirations.
Alexandria Real Estate Equities Inc. is an urban office real estate investment trust focused on collaborative life science, agtech, and technology mega-campuses. The company develops and operates dynamic innovation ecosystems designed to foster scientific discovery and commercial collaboration.
The business operates across premier innovation markets including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. Its properties feature specialized laboratory infrastructure, advanced mechanical systems, and regulatory zoning entitlements tailored to critical research requirements.
The tenant roster spans multinational pharmaceutical companies, biotechnology enterprises, medical device manufacturers, academic institutions, and government research entities. Tenant demand is driven by ongoing biomedical research, product development pipelines, and venture capital funding conditions across the life science sector.
Under a severe stress test, submarket laboratory oversupply combines with prolonged leasing downtime on upcoming contractual expirations. Because in-place leases carry a spot mark-to-market rate approximately 6% above market, roll-downs worse than -15.0% reduce net operating income. Concurrently, elevated interest rates exacerbate the burden of $13.17B in total debt, where high debt weighting of 64.77% elevates WACC to 15.97%, compressing equity value.
Alexandria Real Estate Equities possesses a Narrow economic moat driven by high tenant switching costs and valuable cluster assets in premier life science hubs. Its Class A mega-campuses across Greater Boston, the San Francisco Bay Area, and San Diego concentrate critical biomedical infrastructure, advanced power systems, and zoning entitlements that cannot be replicated easily. Pharmaceutical and biotechnology tenants face significant relocation friction, evidenced by existing tenants accounting for 68% of second-quarter 2026 leasing volume.
The moat remains narrow rather than wide due to supply overhang in secondary submarkets and lease roll-over headwinds. Expiring leases carry a spot mark-to-market premium averaging 6% above market, causing cash renewal spreads to decline -4.3% in second-quarter 2026 and between -7.0% and -15.0% for full-year 2026. Additionally, $13.17B in total debt and elevated cost of capital constrain excess economic return generation.
While core operational mega-campuses produce resilient property yields, consolidated returns on capital are dampened by development carrying costs, elevated debt weight of 64.77%, and property impairments.12
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($43.02). Each row and column shows what Fair value becomes when one assumption moves.
A free-cash-flow drop test is not available in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
Accelerating net operating income growth and faster balance sheet deleveraging would expand cash flow coverage and narrow the gap to Potential value $49.06.
Performance tracking guidance confirms that property support dividend distributions while asset sales proceed at the expected pace.
The REIT industry reflects disciplined reinvestment with average capex-to-revenue of -0.127 and capex-to-depreciation of 0.17. Alexandria is contracting development outlays from $1.87B in FY2025 to a guided $1.15B-$1.65B by FY2027.23
A life science upcycle is characterized by robust venture capital funding, accelerated pharmaceutical research budgets, tight wet-lab vacancy across top innovation clusters, and strong tenant expansion driving positive lease mark-to-market rental spreads.
A downcycle occurs when biotechnology funding contracts, speculative laboratory supply creates high submarket vacancy, and tenant consolidation forces negative renewal rent spreads alongside prolonged leasing downtime.
Position sizing reflects a Hold rating where modest upside of 3.4% to Fair value of $43.02 is tempered by near-term lease renewal headwinds and substantial debt leverage. Maintaining a moderate weighting allows investors to collect dividend distributions while awaiting tangible progress on capital recycling and debt reduction.
Maintain position discipline by monitoring quarterly same-property net operating income and progress on the guided asset disposition program. Limit overall life science real estate exposure within a diversified portfolio.
Durable dividend distributions supported by long-term leases provide steady income, but near-term capital appreciation is capped near Fair value $43.02 until lease roll-downs abate.
At $41.62, shares offer modest upside of 3.4% to Fair value $43.02, which is insufficient margin of safety given total debt of $13.17B.2
Near-term revenue growth is constrained by negative renewal spreads and asset dispositions, limiting fundamental growth catalysts.
Alexandria Real Estate Equities offers modest upside of 3.4% to Fair value of $43.02 relative to its price of $41.62.
While premier life science mega-campuses support high tenant retention and dividend distributions, upcoming lease expirations with negative mark-to-market renewal spreads and substantial debt obligations justify a Hold rating.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
In the downside path, competitive laboratory space oversupply and constrained tenant capital expenditure force deeper rental concessions and extended vacancy downtime. Heavy fixed debt service obligations and delayed capital recycling would exacerbate negative operating leverage. This path would be confirmed by negative double-digit cash renewal spreads and elevated debt-to-operating earnings ratios.
Guidance projects 2026 cash rental rate changes on lease renewals between -7.0% and -15.0%, following a -15.8% drop in 1Q26. Contractual expirations across 2026 (451k RSF) and 2027 (1.38M RSF) face 12 to 24 months of downtime. Sustained cash renewal cuts below -15.0% trigger negative operating leverage and asset impairments.3
Total debt is $13.17B against a debt weight of 64.77%. Computed WACC is 15.97% and credit rating carries a BBB+ Negative outlook. A 200 bps widening in credit spreads or required cost of equity elevates WACC above 17.97%, severely compressing enterprise and equity present values.12
Valuation syntheses anchor on a 16.5x terminal multiple. Real estate impairments of $222.47M in 2Q26 and asset sales to residential developers demonstrate ongoing submarket repricing. A 20% contraction from 16.5x to below 13.2x reflects commercial real estate cap rate expansion and higher risk premia.2
The five developments that would weaken our investment case.
Deeper rental roll-downs signal weakening competitive advantage and reduce property-level net operating income.
Current:-4.3% cash in 2Q26 (-15.8% in 1Q26)
Alert ifbelow -15.0%
Elevated leverage increases refinancing vulnerability and risks credit rating downgrades.
Current:7.0x with $13.17B total debt
Alert ifabove 7.5x
Falling occupancy indicates unabsorbed cluster vacancy and compounds negative operating leverage.
Current:86.9% in 2Q26
Alert ifbelow 85.0%
Execution delays force Alexandria to carry high debt balances and elevated interest expense.
Current:$1.33B completed or pending of $2.9B guidance
Alert ifProceeds falling more than 30% below the $2.9B target
Failure to moderate construction spending sustains negative free cash flow and delays deleveraging.
Current:$1.87B in FY2025
Alert ifabove $2.0B
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
In the Base case, Alexandria achieves Fair value of $43.02 representing a return of 3.4% with a probability of 55.0%. This path requires steady lease absorption across the development pipeline, normalization of construction capital expenditures toward guided levels, and successful completion of planned capital recycling to stabilize leverage. The scenario would be disconfirmed if cash renewal spreads deteriorate deeper than expected or if tenant downtime extends across upcoming expirations.
In the Bull case, Alexandria reaches Potential value of $49.06 representing an attractive return of 17.9% with a probability of 20.0%. This outcome requires a strong rebound in biotechnology venture funding that accelerates life science leasing, returns cash renewal spreads to positive territory, and allows expedited debt repayment through premium asset valuations. The path would be disconfirmed if secondary submarket lab vacancy persists and renewal spreads remain constrained.
Deeper rental roll-downs and delayed capital recycling would exacerbate negative operating leverage and strain debt service capacity.
Alexandria demonstrates sound operational earnings quality supported by long-term leases and high rent collection rates from predominantly investment-grade and large-cap life science tenants. Reported results diverge between accounting net losses, driven by non-cash real estate depreciation and property impairments, and steady property-level operating cash flow. Cash flow durability hinges on preserving occupancy across core mega-campuses and maintaining rental rate discipline on roll-overs.
Consensus earnings expectations have adjusted lower over recent weeks to reflect lease expiration downtime and conservative rent roll-down assumptions for upcoming quarters.
Measures whether Alexandria maintains pricing power against submarket supply; negative spreads erode property net operating income and compress margins.
Extended vacancy between expiring and replacement leases reduces rental revenue aggregation and forces higher tenant improvement outlays.
Dispositions provide liquidity to repay debt without common equity dilution; delays keep interest expense elevated.
Lower construction spend reduces cash burn and transitions the balance sheet toward positive free cash flow.
High occupancy in primary clusters defends cash flow stability and preserves high tenant switching costs.
| $2.11B |
| $2.58B |
| $2.84B |
| $3.05B |
| $2.97B |
| +8.9% |
| Gross profit | $1.49B | $1.79B | $1.98B | $2.14B | $2.05B | +8.3% |
| Operating income | $530.3M | $764.9M | $355.2M | $696.6M | $-990.0M | — |
| Net income | $571.2M | $521.7M | $103.6M | $322.9M | $-1.43B | — |
| EPS (diluted) | $3.82 | $3.18 | $0.54 | $1.80 | $-8.44 | — |
| EBITDA | $1.35B | $1.77B | $1.45B | $1.90B | $360.5M | -28.1% |
| R&D | $0 | $0 | $0 | — | — | -73.6% |
| SG&A | $151.5M | $177.3M | $199.4M | $168.4M | $117.0M | -6.2% |
FY2025 operating cash flow reached $1.41B, supported by steady collections from prime mega-campuses. However, heavy development outlays of $1.87B led to negative free cash flow of -$456.88M and necessitated $911.45M in dividend funding. As construction spending moderates toward $1.15B-$1.65B in FY2027, cash conversion is poised to stabilize.2345
Alexandria is transitioning away from capital-intensive speculative development toward balance sheet preservation. Construction expenditures are guided to moderate from $1.87B in FY2025 toward $1.15B to $1.65B by FY2027. Management targets $2.9B in capital recycling, with $1.33B completed or pending, directing disposition proceeds toward debt repayment to address $13.17B in total debt without common equity issuance.
Historical return on invested capital was depressed by non-cash real estate impairments and peak development spending, but operational return on core mega-campus assets remains steady as deliveries stabilize.
A high computed WACC of 15.97%, reflecting a 64.77% debt weighting, exceeds current accounting returns, underscoring the imperative for asset recycling and debt reduction.
FY2025 operating cash flow reached $1.41B despite net income of -$1.43B caused by non-cash impairments and depreciation of $1.35B.
Dividend distributions ($911.45M in FY2025) are supported by core operating cash flow rather than GAAP earnings.
Capex is guided to decrease from $1.87B in FY2025 to $1.15B-$1.65B in FY2027.
Reduced capital outlays curtail external debt reliance and allow asset sale proceeds to pay down $13.17B in total debt.
Core life science operating properties generated $2.84B of $2.97B total consolidated revenue in FY2025.
Property-level cash flows remain dependable due to 95.4% concentration in high-spec mega-campuses.
| Revenue | $2,970,717,000 |
|---|---|
| Cost of revenue | $922,605,000 |
| Gross profit | $2,048,112,000 |
| Operating expenses | $3,250,387,000 |
| Operating income | -$1,202,275,000 |
| Non-operating items and tax | -$227,295,000 |
| Net income | -$1,429,570,000 |
| Total assets | $34,081,835,000 |
|---|---|
| Cash | $549,062,000 |
| Current assets | $939,781,000 |
| Total liabilities | $14,925,399,000 |
| Current liabilities | $2,182,600,000 |
| Shareholders’ equity | $19,097,648,000 |
| Net income | $322,949,000 |
|---|---|
| Operating inflow | $1,584,963,000 |
| Depreciation and amortization | $1,202,380,000 |
| Stock-based compensation | $59,634,000 |
| Operating cash flow | $1,504,524,000 |
| Operating outflow | $80,439,000 |
| Cash available | $2,165,295,000 |
| Beginning cash | $660,771,000 |
| Investing outflow | $1,510,695,000 |
| Financing outflow | $93,315,000 |
| Net debt issuance | $928,693,000 |
| Share repurchases | $50,107,000 |
| Dividends paid | $898,557,000 |
| Other financing activities | $73,344,000 |
| Exchange-rate effect | $1,438,000 |
| Ending cash | $559,847,000 |
| Investing cash flow | -$1,510,695,000 |
| Financing cash flow | -$93,315,000 |
Source: SEC EDGAR · Filed 2026-01-26 · SEC EDGAR
| Revenue by operating segment | Revenue | Share | YoY |
|---|---|---|---|
| Reportable Segment Aggregation Before Other Operating | $2.8B | 93.7% | -3.2% |
| All Other Segments | $191.3M | 6.3% | 1.3% |
Point-in-time financial data used in the 2026-10-17 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $897.9M | $370.5M | -$65.9M | $393.5M | -$1B | $1.4B | $313.4M | $25.4M | — | $240.3M | — | -$1.5B | $1.1B | — | $141.4M | $467.5M | $4.2B | 4.6% | — | 9.2% | — |
| 2017-12-31 | $1.1B | $739.6M | $169.1M | $450.9M | -$1.1B | $1.6B | $416.8M | $25.6M | — | $312.1M | — | -$1.7B | $1.4B | $141.4M | $277.2M | $777.6M | $4.8B | 16.1% | — | 6.3% | — |
| 2018-12-31 | $1.3B | $899.9M | $379.3M | $570.3M | -$1.4B | $1.9B | $477.7M | $35M | — | $380.6M | — | -$2.2B | $1.6B | $277.2M | $272.1M | $234.2M | $5.5B | 31.8% | — | 5.2% | — |
| 2019-12-31 | $1.5B | $987.1M | $363.2M | $683.9M | -$2.8B | $3.5B | $544.6M | $43.6M | — | $447M | — | -$3.6B | $2.9B | $272.1M | $242.7M | $189.7M | $6.8B | 28.9% | — | 4.2% | — |
| 2020-12-31 | $1.9B | $1.2B | $771M | $882.5M | -$2.4B | $3.3B | $698.1M | $43.5M | — | $533M | — | -$3.3B | $2.8B | $242.7M | $597.7M | $568.5M | $7.6B | 28.2% | — | 3.4% | — |
| 2021-12-31 | $2.1B | $1.4B | $571.2M | $1B | -$6.3B | $7.3B | $821.1M | $48.7M | — | $656M | — | -$7.1B | $5.9B | $597.7M | $415.2M | $25.3B | $8.8B | 25.1% | — | 4.0% | — |
| 2022-12-31 | $2.6B | $1.8B | $521.7M | $1.3B | -$4.9B | $6.2B | $1B | $57.7M | $0 | $757.7M | $1.4B | -$5.1B | $4.2B | $415.2M | $858M | $2.4B | $10.2B | 23.8% | — | 6.1% | — |
| 2023-12-31 | $2.8B | $1.4B | $103.6M | $1.6B | -$857.8M | $2.5B | $1.1B | $82.9M | $0 | $847.5M | $1.2B | -$2.5B | $674.2M | $858M | $660.8M | $618.2M | $11.3B | 24.3% | — | 6.4% | — |
| 2024-12-31 | $3B | $1.9B | $322.9M | $1.5B | -$1.2B | $2.7B | $1.2B | $59.6M | $50.1M | $898.6M | $928.7M | -$1.5B | -$93.3M | $660.8M | $559.8M | $552.1M | $12.2B | 25.2% | — | 7.2% | — |
| 2025-12-31 | $3B | $360.5M | -$1.4B | $1.4B | -$456.9M | $1.9B | $1.4B | $41.1M | $208.2M | $911.5M | $151.9M | $362.1M | -$1.8B | $559.8M | $553.8M | $549.1M | $12.4B | -40.5% | — | — | — |
Alexandria Real Estate Equities Inc. (ARE) trades at 16.7x forward earnings against a peer median of 47.1x. Its EV/EBITDA of 13.2x compares with a peer median of 17.2x. The comparison uses 4 peers: Camden Property Trust, UDR Inc., Weyerhaeuser Company and Federal Realty Investment Trust, as of 2026-10-17.
| Trend | Impact | Note |
|---|
| Biopharmaceutical Research and Development Spending | positive | Long-term drug discovery and biotechnology innovation require specialized wet-lab facilities with advanced power and regulatory certifications. |
| Life Science Laboratory Space Supply Digestion | negative | Delivery of speculative lab space from the 2021-2022 building cycle creates elevated submarket vacancy and competitive concessions across secondary assets. |
| Elevated Commercial Real Estate Financing Rates | negative | Higher debt yields raise refinancing burdens across leveraged real estate balance sheets, demanding capital recycling for debt paydown. |
Alexandria holds a defensible position within Tier-1 innovation clusters like Greater Boston and San Francisco, though elevated spot rents 6% above market leave near-term roll-overs exposed to competitive market concessions.3
| At $41.62 | Maintain existing position | Shares trade near Fair value $43.02, justifying holding current allocations. |
| Substantial discount to $43.02 | Evaluate incremental accumulation | A wider discount to Fair value would provide a sufficient margin of safety against lease downtime risks. |
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
| UDR |
| UDR Inc. |
| $12.7B |
| 61.2x |
| 7.2x |
| 17.2x |
| 13.7% |
| 20.2% |
| WY | Weyerhaeuser Company | $14.1B | 31.7x | 2.1x | 27.7x | 5.0% | 8.0% |
| FRT | Federal Realty Investment Trust | $9.2B | 33.0x | 6.9x | 17.2x | 12.6% | 35.0% |
